Hazel M. Weir

1.6k total citations
18 papers, 931 citations indexed

About

Hazel M. Weir is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Hazel M. Weir has authored 18 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Genetics and 7 papers in Oncology. Recurrent topics in Hazel M. Weir's work include Estrogen and related hormone effects (6 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer therapeutics and mechanisms (4 papers). Hazel M. Weir is often cited by papers focused on Estrogen and related hormone effects (6 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer therapeutics and mechanisms (4 papers). Hazel M. Weir collaborates with scholars based in United Kingdom, United States and South Korea. Hazel M. Weir's co-authors include Nigel D. Stow, N. D. Stow, Simon T. Barry, Anne U. Goeppert, Anne Marie Mazzola, Wai Lin Wong, Sarat Chandarlapaty, Pedram Razavi, Sarah J. Ross and Weiyi Toy and has published in prestigious journals such as Nucleic Acids Research, Cancer Research and Oncogene.

In The Last Decade

Hazel M. Weir

18 papers receiving 912 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hazel M. Weir United Kingdom 14 394 390 326 243 198 18 931
Matthew W. VanBrocklin United States 15 275 0.7× 617 1.6× 270 0.8× 85 0.3× 126 0.6× 32 1.1k
Joan Kyula United Kingdom 21 576 1.5× 460 1.2× 443 1.4× 118 0.5× 86 0.4× 33 1.0k
Dieter Moosmayer Germany 19 395 1.0× 977 2.5× 77 0.2× 101 0.4× 204 1.0× 38 1.3k
Margit Bauer Germany 14 158 0.4× 528 1.4× 127 0.4× 57 0.2× 228 1.2× 26 1.0k
Robert A. Olie Switzerland 16 361 0.9× 1.1k 2.8× 91 0.3× 94 0.4× 93 0.5× 26 1.3k
Björn G. Voldborg Denmark 15 251 0.6× 710 1.8× 161 0.5× 138 0.6× 63 0.3× 31 1.0k
S. van der Flier Netherlands 14 259 0.7× 668 1.7× 426 1.3× 60 0.2× 134 0.7× 18 1.0k
Kathleen A. Scorsone United States 15 350 0.9× 674 1.7× 103 0.3× 63 0.3× 178 0.9× 18 1.0k
Lorenza Penengo Switzerland 22 563 1.4× 1.5k 3.9× 140 0.4× 150 0.6× 164 0.8× 27 1.9k
Judit Jané‐Valbuena United States 7 226 0.6× 698 1.8× 100 0.3× 132 0.5× 189 1.0× 11 958

Countries citing papers authored by Hazel M. Weir

Since Specialization
Citations

This map shows the geographic impact of Hazel M. Weir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hazel M. Weir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hazel M. Weir more than expected).

Fields of papers citing papers by Hazel M. Weir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hazel M. Weir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hazel M. Weir. The network helps show where Hazel M. Weir may publish in the future.

Co-authorship network of co-authors of Hazel M. Weir

This figure shows the co-authorship network connecting the top 25 collaborators of Hazel M. Weir. A scholar is included among the top collaborators of Hazel M. Weir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hazel M. Weir. Hazel M. Weir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Hamilton, Erika, Manish R. Patel, Anne Armstrong, et al.. (2018). A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer. Clinical Cancer Research. 24(15). 3510–3518. 67 indexed citations
2.
Nardone, Agostina, Hazel M. Weir, Oona Delpuech, et al.. (2018). The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British Journal of Cancer. 120(3). 331–339. 43 indexed citations
3.
Hamilton, Erika, Misaal Patel, Andrew J. Armstrong, et al.. (2017). Abstract P6-12-03: A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC). Cancer Research. 77(4_Supplement). P6–12. 1 indexed citations
4.
Bahreini, Amir, Zheqi Li, Peilu Wang, et al.. (2017). Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research. 19(1). 60–60. 101 indexed citations
5.
Toy, Weiyi, Hazel M. Weir, Pedram Razavi, et al.. (2016). Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery. 7(3). 277–287. 269 indexed citations
6.
Toy, Weiyi, Hazel M. Weir, Pedram Razavi, et al.. (2016). Abstract 863: Differential activity and SERD sensitivity of clinical ESR1 mutations. Cancer Research. 76(14_Supplement). 863–863. 1 indexed citations
7.
Ladd, Brendon, Anne Marie Mazzola, Teeru Bihani, et al.. (2016). Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. 7(34). 54120–54136. 22 indexed citations
8.
Savi, Chris De, Robert H. Bradbury, Alfred A. Rabow, et al.. (2015). Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. Cancer Research. 75(15_Supplement). 3650–3650. 4 indexed citations
9.
10.
Jenkins, David W., Sarah J. Ross, Margaret H. Veldman-Jones, et al.. (2012). MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo. Molecular Cancer Therapeutics. 11(8). 1650–1660. 47 indexed citations
11.
Eberlein, Catherine A., Jane Kendrew, Karen McDaid, et al.. (2012). A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene. 32(37). 4406–4416. 74 indexed citations
12.
Kendrew, Jane, Cath Eberlein, Karen McDaid, et al.. (2011). An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding. Molecular Cancer Therapeutics. 10(5). 770–783. 30 indexed citations
13.
Finlay, M. Raymond V., David Acton, David Andrews, et al.. (2008). Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Bioorganic & Medicinal Chemistry Letters. 18(15). 4442–4446. 27 indexed citations
14.
Jones, Clifford D., David Andrews, Andrew Barker, et al.. (2008). Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(24). 6486–6489. 29 indexed citations
15.
Stow, Nigel D., et al.. (1990). Analysis of the binding sites for the varicella-zoster virus gene 51 product within the viral origin of DNA replication. Virology. 177(2). 570–577. 31 indexed citations
16.
Weir, Hazel M. & N. D. Stow. (1990). Two binding sites for the herpes simplex virus type 1 UL9 protein are required for efficient activity of the oriS replication origin. Journal of General Virology. 71(6). 1379–1385. 63 indexed citations
17.
Weir, Hazel M., et al.. (1989). Binding of the herpes simplex virus type 1 UL9 gene product to an origin of viral DNA replication. Nucleic Acids Research. 17(4). 1409–1425. 75 indexed citations
18.
Weir, Hazel M., et al.. (1981). Human kappa-casein as a tumor marker: purification and properties.. PubMed. 4(1-4). 193–204. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew W. VanBrocklin Breakdown of academic impact, for papers by Joan Kyula Breakdown of academic impact, for papers by Dieter Moosmayer Breakdown of academic impact, for papers by Margit Bauer Breakdown of academic impact, for papers by Robert A. Olie Breakdown of academic impact, for papers by Björn G. Voldborg Breakdown of academic impact, for papers by S. van der Flier Breakdown of academic impact, for papers by Kathleen A. Scorsone Breakdown of academic impact, for papers by Lorenza Penengo Breakdown of academic impact, for papers by Judit Jané‐Valbuena
Rankless by CCL
2026